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EDITORIAL
Targeting Epigenetic Mechanisms to Alleviate Alcoholic
Steatosis
Q6 Alcohol-related liver disease (ALD) is a major healthconcern and recent studies have reportedQ4 nearly 1
million alcohol-related deaths from 1999 to 2017 in the
United States.1 ALD is a spectrum of conditionsQ5 that ranges
from early steatosis or fatty liver to inﬂammation or alco-
holic steatohepatitis progressing to ﬁbrosis and cirrhosis.
Approximately 8%–20% of alcoholic steatohepatitis pa-
tients develop cirrhosis and, in some, alcoholic steatohepa-
titis can present in the form of acute-on-chronic liver failure,
termed alcoholic hepatitis, owing to excessive drinking epi-
sodes. Corticosteroids are the ﬁrst line of therapy for ALD,
however, only marginal short-term survival beneﬁt in pa-
tients with severe alcoholic hepatitis has been reported.2
Studies from the National Institute on Alcohol Abuse and
Alcoholism consortia have focused on preclinical or early
clinical testing of drugs classiﬁed on the basis of pathogenic
mechanisms such as targeting the gut–liver axis, anti-
inﬂammatory agents, antioxidants, and drugs that pro-
motes liver regeneration.3 Despite several efforts, the
treatment for alcoholic hepatitis remains suboptimal and
there is an urgent need to develop new, safe, and effective
therapies. Uncovering new targets directly involved in reg-
ulatory processes that inﬂuence gene expression and
cellular phenotype could be an attractive strategy.
Epigenetic regulatory mechanisms are essential for
orchestrating gene expression and cellular function.
Increasing evidence has shown that acute and chronic alcohol
exposure in vitro and in vivo regulate epigenetic mechanisms
in the liver, brain, and gut, likely contributing to ALD.4 Mul-
tiple modiﬁcations including acetylation, methylation, and
phosphorylation of histones inﬂuence transcriptional acti-
vation or repression of target genes in alcoholic liver. Alcohol
can alter histone acetyl transferases and histone deacetyl
transferase (HDAC) activity to modify histone lysine residues
and regulate histone–DNA interactions resulting in anopenor
closed chromatin state to induce or repress target genes
respectively, in the liver. Livers from alcoholic hepatitis pa-
tients show alterations in DNA methylation and chromatin
remodeling owing to defective hepatocyte nuclear factor-
4a–dependent gene expression.5 Overall previous reports
and recent ﬁndings emphasized that alcohol alters epigenetic
mechanisms contributing to ALD.
In this issue of Cellular and Molecular Gastroenterology
and Hepatology, building on their own group’s earlier re-
ports, Donde et al6 present novel ﬁndings that chronic
alcohol induces histone H3KQ7 9 deacetylation in the promoter
region of the fatty acid oxidation gene, carnitine
palmitoyltransferase-1A (CPT-1A), indicating a closed or
repressive chromatin state and hence reduced CPT-1A geneQ8
expression in alcoholic steatotic livers. Their results showed
that alcohol facilitated HDAC1 binding to CPT-1A promoter
regions I (proximal) and II (distal), causing histone H3K9
deacetylation. Interestingly, transcriptional factors SP1 and
hepatocyte nuclear factor-4a interacted directly with
HDAC1 in the CPT-1A gene proximal and distal promoters to
mediate transcriptional repression. Previous studies by this
group reported that acute alcohol-induced down-regulation
of CPT-1A also involved transcriptionally repressive histone
de-acetylation mediated by the N-CoR Q9-HDAC3 nuclear
receptor corepressor complex, binding only to the distal
CPT-1A promoter region.7 It is noteworthy that chronic
alcohol-mediated HDAC1-induced deacetylation occurs in
the distal and proximal promoter, without any role for the
N-CoR-HDAC3 complex. These studies point to distinct
regulation of the CPT-1A promoter by acute and chronic
alcohol Q10and yet similar outcomes of reduced CPT-1A gene
expression. Previous studies have shown that alcohol
administration in vivo regulates peroxisome proliferator
receptor a in hepatocytes and prevents induction of CPT-1A
expression, affecting fatty acid oxidation.8 Future studies to
investigate whether HDACs and peroxisome proliferator
receptor a act in concert to repress CPT-1A during ALD will
provide important mechanistic insights.
Gut dysbiosis and intestinal permeability are important
triggers in ALD and considerable evidence supports the
premise that the “gut–liver axis Q11” plays a crucial role.9 Undi-
gested dietary polysaccharides can be converted bymicrobial
fermentation to short-chain fatty acids, including butyrate,
which is the primary energy source in the colon and con-
tributes to normal colonic health. In fact, butyrate is a HDAC
inhibitor and can repress target gene expression. Ethanol
consumption decreases short-chain fatty acids, particularly
butyrate, likely owing to the alterations in the microbiome.10
The use of tributyrin, a butyrate prodrug that when admin-
istered orally is hydrolyzed to butyrate, increases its con-
centration in circulation/plasma. Donde et al6 administered
tributyrin by oral gavage, resulting in increased butyrate in
portal blood and liver, preventing steatosis and injury. Trib-
utyrin induced transcriptional activation of CPT-1A promoter
likely owing to decreased histone H3K9 deacetylation in the
liver. Mechanistic in vitro experiments using chromatin
immunoprecipitation analysis have shown that sodium
butyrate inhibits alcohol-induced HDAC1 recruitment to the
CPT-1A promoter, preventing histone deacetylation.
Concomitantly, butyrate treatment facilitated recruitment of
p300-histone acetyltransferase to the CPT-1A distal and
proximal promoter, leading to promoter histone acetylation,
Pol Q12II recruitment, and CPT-1A transcription. Previous
studies have reported that tributyrin treatment during
alcohol feeding decreased liver Toll-like receptor and tumor
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necrosis factor a expression and also prevented ethanol-
induced disruption of intestinal tight junction proteins and
intestinal permeability.11 The current study extends the
beneﬁcial effect of tributyrin to alcoholic steatosis in ALD.
Q15 In summary, Donde et al6 presented novel ﬁndings on
ethanol-mediated inhibition of CPT-1A promoter via HDAC1
activity and histone deacetylation in hepatocytes contrib-
uting to alcoholic steatosis and liver injury. Furthermore,
the beneﬁcial effect of tributyrin on alcoholic steatosis by
inhibition of HDAC1 activity and increased recruitment of
p300 promoting CPT-1A gene expression also has been re-
ported. These studies point to the potential of targeting
HDAC1 using drugs/inhibitors in ALD. Furthermore, the
clinical relevance of restoring intestinal and circulating
butyrate levels as a therapeutic strategy also may be an
attractive option for
Q16
alcoholic hepatitis treatment.
PRANOTI MANDREKAR, PhD
Department of Medicine
University of Massachusetts Medical School
Worcester, Massachusetts
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